drugset / Trial / NCT02998450
A Study of IMR-687 in Healthy Adult Volunteers
Phase 1
Completed
66 enrolled
Cardurion Pharmaceuticals, Inc.
Imara, Inc. · collabQuintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
Timeline
- Start
- 2016-10-18
- Primary completion
- 2017-07-08
- Completion
- 2017-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tovinontrine | Small molecule | — | Oral |